Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
Marjon V VerschuerenTalitha DijsJudith L GulikersArd van VeelenSander CroesLizza E L HendriksAdrianus Aj SmitLourens T BloemAntoine C G EgbertsEwoudt M W van de GardeBas Jm PetersPublished in: Immunotherapy (2023)
Aim: We investigated the effectiveness of durvalumab post-concurrent CRT (cCRT) and post-sequential CRT (sCRT) versus cCRT and sCRT alone and compared these outcomes with the PACIFIC trial. Methods: Four cohorts of stage III NSCLC patients who received CRT were included: cCRT with and without durvalumab, sCRT with and without durvalumab. PFS and OS were analyzed using Cox regression. Results: Durvalumab improved PFS (cCRT: aHR = 0.69, sCRT: aHR = 0.71) and OS (cCRT: aHR = 0.71, sCRT: aHR = 0.32), although not all results were significant. PFS was longer in the real-world than in the trial, while OS did not differ. Conclusion: Durvalumab after CRT improved the survival outcomes. The difference between PFS in our study and the trial may be due to differences in follow-up methods.
Keyphrases
- clinical trial
- phase iii
- phase ii
- study protocol
- cardiac resynchronization therapy
- randomized controlled trial
- open label
- systematic review
- locally advanced
- rectal cancer
- heart failure
- squamous cell carcinoma
- type diabetes
- radiation therapy
- weight loss
- adipose tissue
- epidermal growth factor receptor
- advanced non small cell lung cancer